Concr recognised as a top Cambridge spinout changing the story of cancer

21 Oct 2024

Concr was featured in a recent story authored by the Cambridge Enterpise as one of 10 spinouts from the Cambridge cluster turning ideas into reality with potential to change the lives of cancer patients.

Concr was founded in Cambridge, building on the research of its co-founder and Chief Technical Officer Dr. Matthew Griffiths of the Cavendish Laboratory (Department of Physics) at the University of Cambridge. As part of the feature, Dr Griffiths commented: “The key determinant to a company's success is the quality of the people that you can draw to your vision. The tight networks within Cambridge which can be accessed through the many supporting organisations have provided critical access to the investors, advisors, experts, champions, customers and talent that Concr has relied upon to succeed and grow.”

  • To read the story and see the full list, click here.

Cambridge Enterprise is the commercialisation arm of the University of Cambridge, supporting companies operating in the cutting edge of science and technology with close ties to the world-leading Cambridge innovation ecosystem. Cambridge Enterprise co-led Concr’s £1.94 million seed round in 2023 alongside existing investors, including Cambridge Angels, a network of esteemed investors with proven experience as successful entrepreneurs.

Get in touch
For investment enquiries: irina@concr.co
For media enquiries: emre@concr.co


Back